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Abstract
Introduction Cardiovascular diseases are the leading
cause of morbidity and mortality among individuals
with diabetes. Despite the beneficial effects of
antidiabetic drugs (ADDs) in terms of lowering
haemoglobin A1c, several ADDs have been shown to
increase the risk of cardiovascular events. Given the
high prevalence of cardiovascular disease among
individuals with diabetes, it is important to weigh
the benefits of ADDs against their cardiovascular
safety. Therefore, the objective of the current study
is to conduct a systematic review with network
meta-analysis to compare the effects of different oral
pharmacological classes of ADDs on cardiovascular
safety.
Methods and analysis Randomised clinical trials
(RCTs) and observational studies published in
English up to 31 January 2017, and which include
direct and/or indirect evidence, will be included.
Studies will be retrieved by searching four electronic
databases and cross-referencing. Dual selection
and abstraction of data will occur. The primary
outcome will be cardiovascular mortality. Secondary
outcomes will include all-cause mortality, new event
of acute myocardial infarction, stroke (haemorrhagic
and ischaemic), hospitalisation for acute coronary
syndrome and urgent revascularisation procedures.
Risk of bias will be assessed using the Cochrane
Risk of Bias assessment instrument for RCTs and the
Strengthening the Reporting of Observational Studies
in Epidemiology instrument for observational studies.
Network meta-analysis will be performed using
multivariate random-effects meta-regression models.
The surface under the cumulative ranking curve will
be used to provide a hierarchy of ADDs that increase
cardiovascular mortality.
Dissemination The results of this study will be presented
at a professional conference and submitted to a peerreviewed journal.
PROSPERO registration number CRD42017051220.

Introduction
Rationale
Diabetes is a global public health problem,
with prevalence expected to increase from
382 million to 592 million people by 2035.1

Strengths and limitations of this study
►► To the best of our knowledge, this is the first

systematic review with network meta-analysis that
compares the cardiovascular safety of different
classes of antidiabetic drugs based on data
from both randomised clinical trials (RCTs) and
observational studies.
►► Common to most meta-analyses, significant and
unexplained heterogeneity may exist.
►► Like any aggregate data meta-analysis, the risk for
ecological fallacy exists.
►► Few RCTs may report data on cardiovascular
mortality.

It is the seventh leading cause of death in
the USA, with cardiovascular (CV) disease
being the most common cause of death
from diabetes.2 Importantly, type 2 diabetes
mellitus (T2DM) more than doubles the risk
of CV events.3 4 Annual per-person medical
care cost of treating adults with T2DM and
CV disease is US$10 172, approximately
two times greater than the cost of treating
T2DM alone.5
Pharmacotherapy is the mainstream
strategy to manage diabetes by controlling
haemoglobin A1c (HbA1c), which is
important to reduce the risk of CV events
and premature mortality.6 7 However, in 2007,
the safety of rosiglitazone, a member of the
thiazolidinedione class of antidiabetic drugs
(ADDs), was questioned.8 Specifically, rosiglitazone was found to be associated with an
increased risk of heart attacks, stroke and
mortality from CV events.8 In addition to
rosiglitazone, the CV safety of several other
ADDs, including pioglitazone and sulfonylureas, has been questioned.9–15 For example,
while dipeptidyl peptidase-4 inhibitors
(DPP-4Is) were shown to be associated with
decreased hospitalisation due to heart failure
in one study,16 another study reported a
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higher rate of hospitalisation due to heart failure among
those using DPP-4Is.17 Based on the potential deleterious
consequences of ADDs and subsequent CV events, the US
Food and Drug Administration (FDA) revised their policy
in 2008 to place greater emphasis on examining CV safety
for all trials testing newer ADDs.18 However, the effects
of ADDs on CV events, including CV mortality, have not
been firmly established.8 10 To the best of the authors’
knowledge, only one previous network meta-analysis has
been conducted with respect to the CV safety of ADDs.19
In this study, authors included randomised clinical trials
(RCTs) that were 24 weeks or longer. No statistically
significant difference was reported between CV mortality
and any drug class. While these findings are encouraging,
the inclusion of only RCTs may be potentially limiting,
given that prior to 2008, ADDs were only required to
prove clinical efficacy in terms of lowering HbA1c. As a
result, the clinical trials of the drugs that received regulatory approval before 2008 may not have reported CV
outcomes. Consequently, a need exists for a meta-analysis
that includes both RCTs and observational studies so that
adverse outcomes can be appropriately documented. In
addition, it has recently been suggested that RCTs and
observational studies should not be considered in isolation.20 Furthermore, additional studies may have been
published since the previous studies search for eligible
trials (21 March 2016).19 Given the former, a need exists
for an updated network meta-analysis that also includes
observational studies.
Objective
The primary objective of this study is to conduct a systematic review with network meta-analysis of randomised
trials and observational studies to compare the effects
of different pharmacological classes of ADDs on CV
mortality. The network meta-analytic approach is
appropriate here because it allows for the inclusion
of multiple interventions from both direct and indirect comparisons that have not been examined in a
head-to-head fashion.21

Methods
Overview
This study will follow the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines22 for
meta-analyses of healthcare interventions and the current
protocol report follows the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses Protocols.23
This protocol is registered in International Prospective
Register of Systematic Reviews (trial registration number:
CRD42017051220).
Eligibility criteria
Studies that meet the following criteria will be included:
(1) randomised trials and observational studies; (2)
adults ≥18 years of age with T2DM, either with or
without a history of CV disease; (3) at least one oral
2

ADD intervention group; (4) comparative control
group for randomised trials that do not include more
than one oral ADD; (5) data on CV mortality and/
or major adverse cardiac events; (6) studies published in
English up to 31 January 2017. The decision to include
patients with T2DM with or without a history of CV
disease was made based on our preliminary search of
clinical trials that included patients with either a history
of CV disease or those who are at a heightened risk for
CV disease. Because T2DM and a history of CV disease
are both associated with an increased risk of acute
myocardial infarction (AMI) and stroke,24 we decided
to include patients with T2DM with or without a history
of CV disease and compare new events of AMI and
stroke between the two groups. Such criteria will also
allow for selected comparisons. A decision was made to
only include oral ADDs because there are two classes
of injectable antidiabetic medications approved for
treatment in the USA. These include insulin and glucagon-like peptide-1 receptor agonists. Typically, insulin
and other injectable drugs are not first-line therapies in
the treatment of T2DM. These are prescribed to more
severe patients who are not able to achieve appropriate
glucose levels with other therapies. Therefore, to keep
the study population more uniform, only oral antidiabetic agents will be included.
Direct comparisons will be made from the studies
comparing two or more ADDs and indirect comparisons will be made from studies comparing an ADD to
a placebo. Both randomised clinical trials and observational studies will be included because randomised clinical trials were not required to include CV outcomes
before 2008, and it has recently been suggested that RCTs
and observational studies should not be looked at in isolation.20 Major adverse cardiac events will be defined as an
incidence of AMI, stroke, hospitalisation for acute coronary syndrome and urgent revascularisation procedures.
These measures were identified by the US FDA to ascertain the CV safety of ADDs in the regulatory guidelines
issued for the industry.18
Information sources
The following databases will be searched from their
inception forward for potentially eligible studies in
English language published on or before 31 January
2017: (1) PubMed, (2) Scopus, (3) Web of Science, (4)
Cochrane Central Register of Controlled Clinical Trials,
(5) clinical trials registry (ClinicalTrials.gov). In addition,
cross-referencing from retrieved studies will be conducted.
Search strategy
Search strategies adapted from a previous research19 will
be developed using text words and Medical Subject Headings. Electronic databases will be searched for studies
on the effects of oral ADDs on CV safety in adults with
T2DM. The first author will conduct all database searches.
A preliminary search strategy for PubMed is shown in
online supplementary file 1. The search strategy for all
Goyat R, et al. BMJ Open 2017;7:e017644. doi:10.1136/bmjopen-2017-017644
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other databases will be adapted based on the requirements of each database.
Study records
Study selection
All studies extracted from electronic databases using the
search strategy will be imported into EndNote V.X7.5.
Duplicate studies will be removed electronically using
the ‘Find Duplicates’ tool in EndNote. The studies will
be examined again manually to find and delete any additional duplicates. The first two authors will select studies
independent of each other. Complete articles will be
obtained for all titles and abstracts that appear to meet
the inclusion criteria or where there is any uncertainty.
Reasons for exclusion will be coded as one or more of
the following: (1) inappropriate population, (2) inappropriate intervention, (3) inappropriate comparison,
(4) inappropriate outcome(s), (5) inappropriate study
design and (6) other. After selection, the first two authors
will review their selections and resolve any discrepancies
by consensus. If consensus cannot be reached, the third
author will be consulted. The overall agreement rate
prior to correcting discrepant items will be calculated
using Cohen’s kappa (κ) statistics. Once discrepancies are
resolved, the overall precision of searches will be calculated by dividing the number of studies included by the
total number of studies screened after removing duplicates. The number needed to read will then be calculated

Figure 1

as the inverse of the precision. A flow diagram that depicts
the search process and an online supplementary file that
includes a reference list of all studies excluded (including
the reason(s) for exclusion) will be included in the study.
The proposed structure for the flow diagram is shown in
figure 1.
Data abstraction
Before initiating data abstraction, a codebook will be
developed in Microsoft Excel 2013. The codebook will be
developed by the first author with input from the third
author. The major categories of variables to be coded will
include: (1) study characteristics (author, journal, year,
etc); (2) participant characteristics (age, sex, HbA1c, CV
disease at baseline, etc); (3) intervention characteristics
(pharmacological class of ADDs, dose, route of administration, etc); (4) control characteristics; (5) outcome
data for CV mortality, all-cause mortality, incidence of
AMI, stroke, hospitalisation for acute coronary syndrome
and urgent revascularisation procedures. The first two
authors will abstract data from selected studies, independent of each other, using the codebook in Microsoft Excel. On completion, both authors will review
the codebooks and resolve discrepancies by consensus.
If consensus cannot be reached, the third author will
provide a recommendation. Prior to correcting disagreements, the overall agreement rate will be calculated using
Cohen’s κ statistic.

Flow diagram of study selection process.
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Outcomes and prioritisation
The primary study outcome will be CV mortality.
Secondary outcomes will include all-cause mortality, new
event of AMI, stroke, hospitalisation for acute coronary
syndrome and urgent revascularisation procedures.
Risk of bias assessment in individual studies
Risk of bias for RCTs will be assessed using the Cochrane
Risk of Bias instrument.25 Observational studies will be
assessed using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) instrument.26 Bias in RCTs will be evaluated for six domains:
(1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4)
blinding of outcome assessors, (5) incomplete outcome
data and (6) selective reporting. Each study will be classified as having a high, low or unclear risk of bias overall
and for each domain. The overall risk of bias will be classified as high if any one of the domains is considered
high risk. The STROBE instrument is a checklist of 22
items that evaluates the quality of reporting for observational studies. No study will be excluded based on the
results of risk of bias assessment.26 The first two authors
will conduct all risk of bias assessments independent of
each other. The two authors will then review the results
for risk of bias assessment and resolve any discrepancies
by consensus. If consensus cannot be reached, the third
author will be consulted.
Data synthesis
Calculation of effect sizes
All analyses will be conducted using the natural log of
OR and then transformed back to ORs for presentation
purposes. If OR is not reported, it will be calculated
from data reported in the study. If data are not available to calculate OR, it will be requested from the study
authors. Secondary outcomes will be calculated using
the same procedure as for our primary outcome. If a
study includes both direct and indirect comparisons,
only direct comparison data will be included given that
the primary focus of the current study is to compare the
CV safety between different ADDs. The data augmentation approach will be used to make direct comparisons if
the control group is placebo.27 In this technique, direct
evidence studies that lack a control (placebo) group
will have one generated from the weighted average of
the arm-specific means and SD.28
Pooled estimates for change in outcomes
Network maps will be drawn to depict the treatments
that are directly compared against each other and the
amount of evidence available for each treatment and its
comparator. Separate network maps will be presented for
each outcome. Contribution plots for each outcome will
be generated to determine the most dominant comparisons for each network estimate, as well as for the entire
network. The weights applied will be a function of the
variance of the direct treatment effect and the network
4

structure, the product being a per cent contribution
of each direct comparison to each network estimate.
Network and contribution plots will be produced using
the networkplot and netweight commands, respectively,29 in
Stata/IC for Mac V.14.0 (STATA; 2016).
Prior to conducting network meta-analysis, pairwise meta-analysis using random-effects models will be
conducted in order to examine statistical heterogeneity
within each comparison.21 Heterogeneity will be assessed
using Cochran’s Q statistics and I2, an extension of Q.30 31
A Q statistic <0.10 and/or an I2 value >50% will be considered to represent significant heterogeneity. On completion of pairwise meta-analysis, network meta-analysis will
be performed using multivariate random-effects models
based on the mvmeta command in Stata/IC for Mac
V.14.0.32 Non-overlapping 95% CIs will be considered
to represent statistically significant changes. Separate
network meta-analysis models will be used to compare CV
mortality, all-cause mortality, incidence of AMI, stroke,
hospitalisation for acute coronary syndrome and urgent
revascularisation procedures.
Sub-group analyses will be conducted to examine the
association between our primary outcome and oral ADDs.
These will include year of drug approval by the US FDA,
presence or absence of CV disease risk at baseline, HbA1c
at the baseline, number of comorbidities, type of treatment (monotherapy, dual therapy or triple therapy)
and the country the study was conducted in. Secondary
outcomes will be handled using the same approach.
We will examine the consistency of the estimates of
treatment effects from direct and indirect evidence for
each outcome using the mvmeta command in Stata.28 An
alpha value <0.05 will be considered to represent statistically significant inconsistency. Prediction intervals
will be used to enhance the interpretation of findings
and provide an estimate of expected results in a future
study.28 32 Prediction intervals will be generated using
the mvmeta and interval plot29 commands in Stata/IC
for Mac V.14.0.
Meta-biases
Small-study effects (publication bias, etc) will be assessed
using comparison-adjusted funnel plots. Unlike traditional funnel plots in pairwise meta-analysis, funnel plots
in network meta-analysis need to account for the fact that
studies estimate treatment effects for different comparisons. Consequently, there is no single reference line from
which symmetry can be evaluated. For the comparison-adjusted funnel plot, the horizontal axis will represent the
difference between study-specific effect sizes from the
comparison-specific summary effect. In the absence of
small-study effects, the comparison-adjusted funnel plot
should be symmetric around the zero line. Since the
treatments need to be organised in some meaningful way
to examine how small studies may differ from large ones,
comparisons will be defined so that all refer to an active
treatment versus a control group. Comparison-adjusted
Goyat R, et al. BMJ Open 2017;7:e017644. doi:10.1136/bmjopen-2017-017644
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Table 1 Covariates that will be included in the study
Characteristics Variables
Study
Participant

Publication year, country the study was conducted in, type of study (RCT, cohort, case–control, etc),
duration of the study, follow-up duration.
Age, sex, HbA1c, risk of cardiovascular disease, presence or absence of cardiovascular disease, medication
status, baseline condition of participants (eg, disease severity).

Intervention

Name of the drug, pharmacological class, dose, route of administration.

Comparator
Outcome

Name of the drug, pharmacological class, dose, route of administration.
Cardiovascular mortality, all-cause mortality, incidence of AMI, stroke, hospitalisation for acute coronary
syndrome and urgent revascularisation procedures.

AMI, acute myocardial infarction; HbA1c, haemoglobin A1c; RCT, randomised clinical trial.

funnel plots will be generated using the netfunnel
command29 in Stata/IC for Mac V.14.0.
Transitivity (similarity in the distribution of potential
effect modifiers across the different pairwise comparisons)33 will be evaluated using random-effects network
meta-regression while controlling for the different study
designs within each comparison. Potential effect modifiers will include age, gender, baseline HbA1c, duration
of T2DM, obesity, presence of CV disease at baseline and
medication status. In addition, because individuals taking
medication are more likely to have severe disease or more
comorbidity than those without medication, we will also
include baseline condition of the patient (eg, disease
severity) in our regression models. However, since this is an
aggregate data meta-analysis and if the patients included
within each study are heterogeneous (eg, different levels
of disease severity within the same study), we will include
as a covariate those studies that control for such factors
versus those that do not. Table 1 provides a complete list
of covariates that we plan to include. Transitivity analysis
will be conducted using the mvmeta command28 in Stata/
IC for Mac V.14.0.
Ranking analysis is a major advantage of network
meta-analysis because it allows one to rank all interventions for the outcome of interest. For the current study,
we will generate ranking plots for a single outcome using
probabilities.34 35 However, since ranking treatments
based solely on the probability of each treatment being
the best does not account for the uncertainty in the relative treatment effects and the potential for assigning
higher ranks in which little information is available,
rankograms and cumulative ranking probability plots will
be used to show ranking probabilities along with their
uncertainty for changes in our primary and secondary
outcomes.34 35 Surface under the cumulative ranking
curves (SUCRA), a transformation of mean ranks,
will be used to provide a hierarchy of treatments while
accounting for the location and variance of all treatment
effects.34 35 Larger SUCRA values are indicative of better
ranks for the treatment. Separate ranking analyses will be
conducted for all primary and secondary outcomes using
the mvmeta28 and SUCRA29 commands in Stata/IC for
Mac V.14.0.
Goyat R, et al. BMJ Open 2017;7:e017644. doi:10.1136/bmjopen-2017-017644

Software used for data synthesis
All data will be analysed using Stata/IC for Mac V.14.0.
Confidence in the cumulative evidence
Strength in the body of evidence will be assessed using
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) instrument for
network meta-analysis.36 Two main outputs are reported
in a network meta-analysis: pairwise effect estimates and
treatment rankings. Since the two outputs are generated using different techniques, they may differ between
each other. Therefore, it is important to assess the level
of confidence to be placed on each output. The level
of confidence will be assessed using GRADE across four
domains: (1) study limitations, (2) joint consideration
of indirectness and transitivity, (3) joint consideration
of statistical heterogeneity and statistical inconsistency,
(4) imprecision and publication bias. Based on these
assessments, the overall strength of evidence will be
ranked as either high, moderate, low or very low. The
overall confidence will be classified as high if any one of
the domains is considered high.
Registration
In accordance with Primary Reporting Items for
Systematics Reviews and Meta-Analyses Protocols (PRISMA-P,) our systematic review with network meta-analysis
was registered with the International Prospective Register
of Systematic Reviews (PROSPERO) on 15 April 15, 2017
(registration number: CRD42017051220).
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